Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase II Investigation of TAS-102 in Patients With High Grade, Extrapulmonary Neuroendocrine Carcinoma

NCT04042714 is registered in ClinicalTrials.gov with Baylor Research Institute as lead sponsor.

NCT NCT04042714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04042714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase II Investigation of TAS-102 in Patients With High Grade, Extrapulmonary Neuroendocrine Carcinoma
Lead sponsor
Baylor Research Institute
Phase
Phase 2
Overall status
Terminated
Start date
August 15, 2019
Completion date
October 15, 2025
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade extra pulmonary neuroendocrine cancer